Prognostic value of serum il-10 and soluble il-2 receptor level in aggressive non hodgkin's lymphomas

Abstract EN

Combination chemotherapy has transformed aggressive NHL from a fatal disease into one that is often curable.

However, many patients still die of their disease, underscoring the need of more accurate methods of prospectively identifying patients with different long term prognosis.

In this study we aim to explore the ability of the combined detection of soluble IL-2 receptor (sIL-2R) and interleukin-10 (IL-10) to predict treatment failure in patients with aggressive non-Hodgkin's lymphoma (NHL).

Sixty patients with aggressive NHLs were included in the study.

All cases were subjected to history taking, clinical examination, intensive laboratory and radiological investigations and special investigations including ESR, serum LDH, serum IL-10 and serum sIL-2R before and after treatment with 4 doses of CHOP regimen.

According to response to treatment they were divided into 3 groups (group I including patients with complete response, group II patients with partial response and group III patients with no response to treatment).

The obtained results showed significant difference in the mean values of ESR mm / h in groups I, II and III before and after treatment.

The results showed significant difference in the mean values of LDH / L, IL-10 pg / ml and sIL-2R IU / mL in group I before and after treatment with no significant difference before and after treatment in both group II and group III.

It also showed significant difference between ESR and IL-10 in relation to clinical stage of the disease, significant difference in sIL-2R between patients with stage II and stage III, IV, a significant difference between ESR, sIL-2R and bulkiness of the tumor and significant difference between IL-10 and bulkiness of the tumor.

IL-10 and sIL-2R levels declined to normal range in responding patients whereas they remained elevated in partially responder and non-re-spender patients.

Finally the results showed that IL-10 was the only associated risk for failure of treatment induction in univariate analysis but IL-10 and sIL-2R maintained their prognostic significance with multivariate logistic regression analysis.

We can conclude that, the detection of pretreatment levels of serum IL-10 and sIL-2R are of prognostic value in patients with aggressive NHLs with high tumor mass who would probably require different strategies and therapeutic reinforcement.